Checked
Aptevo Therapeutics Inc.
Nasdaq: APVO · Pharmaceutical Preparations · Seattle, WA
- Net income
- -$25.97M
- Total assets
- $27.19M
- Diluted EPS
- -$87.27
Company details
As reported to the SEC
- SEC CIK
- 1671584
- Stock
- Nasdaq: APVO
- Legal Entity Identifier (LEI)
- 529900UTQOXOZBMZFN24
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 2401 4th Ave., Suite 1050, Seattle, WA 98121
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (206) 838-0500
- Employer ID (EIN)
- 81-1567056
- Last annual report
- 03/26/2026
- Last quarterly report
- 08/14/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | Not reported | Not reported | Not reported | $3.11M | $12.29M |
| Operating income | -$26.31M | -$24.6M | -$28.88M | -$28.64M | -$21.4M |
| Net income | -$25.97M | -$24.13M | -$17.41M | $8.03M | -$28.46M |
| Diluted earnings per share | -$87.27 | -$31460.23 | -$2316.83 | $1.57 | -$6.07 |
| Research and development | $14.54M | $14.38M | $17.11M | $17.88M | $18.99M |
| Total assets | $27.19M | $15.59M | $24.84M | $34.22M | $56.6M |
| Total liabilities | $9.81M | $10.84M | $12.62M | $16.24M | $55.38M |
| Shareholders' equity | $17.38M | $4.75M | $12.22M | $17.97M | $1.22M |
| Cash and cash equivalents | $21.62M | $8.71M | $16.9M | $22.64M | $45.04M |
| Long-term debt | Not reported | Not reported | $0 | $1.46M | $3.71M |
| Cash from operations | -$25.59M | -$23.79M | -$11.73M | -$21.02M | -$21.68M |
| Capital expenditures | Not reported | Not reported | Not reported | $29K | $713K |
Subsidiaries
1 company that Aptevo Therapeutics Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Aptevo Research and Development LLC | SEC 10-K |
Recent filings
141 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KOther events | 10/26/2026 | 10/26/2026 |
| 8-KMaterial agreement, Change to shareholder rights | 10/23/2026 | 10/23/2026 |
| 8-KOther events | 10/14/2026 | 10/14/2026 |
| S-8Registration of employee stock plan shares | 09/25/2026 | None |
| 8-KOther events | 09/24/2026 | 09/24/2026 |
| 8-KShareholder vote results | 09/23/2026 | 09/22/2026 |
| 424B4Prospectus | 09/03/2026 | None |
| 8-KOther events | 09/03/2026 | 09/03/2026 |
| EFFECTNotice of effectiveness | 09/02/2026 | None |
| CORRESPLetter to the SEC staff | 08/31/2026 | None |
| DEF 14AProxy statement | 08/31/2026 | 09/22/2026 |
| UPLOADLetter from the SEC staff | 08/27/2026 | None |
| DNotice of exempt offering (Form D) | 08/26/2026 | None |
| PRE 14APreliminary proxy statement | 08/21/2026 | 08/21/2026 |
| S-1Registration statement (new securities) | 08/21/2026 | None |
| 8-KShareholder vote results | 08/21/2026 | 08/21/2026 |
| SCHEDULE 13G/AOwnership report (5% holder, passive, amended) | 08/14/2026 | None |
| 10-QQuarterly report | 08/14/2026 | 06/30/2026 |
| 8-KResults of operations | 08/14/2026 | 08/14/2026 |
| 8-KMaterial agreement, Unregistered sale of shares, Other events | 08/13/2026 | 08/12/2026 |
13 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Aptevo Therapeutics Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Aptevo Therapeutics Inc.'s CIK number?
- Aptevo Therapeutics Inc.'s SEC Central Index Key (CIK) is 1671584.
- What is Aptevo Therapeutics Inc.'s stock ticker?
- Aptevo Therapeutics Inc. trades as Nasdaq: APVO.
- When does Aptevo Therapeutics Inc.'s fiscal year end?
- Aptevo Therapeutics Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Aptevo Therapeutics Inc. headquartered?
- Aptevo Therapeutics Inc.'s principal executive office on file with the SEC is in Seattle, WA.
- What companies does Aptevo Therapeutics Inc. own?
- Aptevo Therapeutics Inc. lists 1 subsidiary in its SEC filings and other public records, including Aptevo Research and Development LLC.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026